Seagen Inc. (Nasdaq: SGEN) has announced that the U.S. Food and Drug Administration (FDA) has approved Adcetris® (brentuximab vedotin) for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. Originally approved by the FDA on August 19, 2011, Adcetris (brentuximab vedotin) injection is a CD30directed antibody-drug conjugate (ADC) used for the treatment of Hodgkin lymphoma, anaplastic large cell lymphoma, and mycosis fungoides. 5 Drug News – Volume 9, Issue 12
